News

News

Hong Kong Financial Secretary Paul Chan Mo-po Leads Delegation to Inspect Chia Tai Tianqing, Jiangsu and Hong Kong Join Hands to Build a New Global Gateway

Release Date: 2026-10-15

On October 14, Paul Chan Mo-po, Financial Secretary of the Government of the Hong Kong Special Administrative Region, led a delegation to continue their visit in Nanjing and visited Chia Tai Tianqing Pharmaceutical Group, a core enterprise under Biopharmaceutical Limited (SBP Group, 01177.HK), to inspect the company's achievements in innovation and development on-site. Cheng Cheung Ling, President of the Hong Kong China Friendship Association, Founding President of the Hong Kong Belt and Road General Chamber of Commerce, President of CP Pharmaceutical Group, and Vice Chairman of the Board of SBP Group, delivered a welcome speech. Zhang Xin, Deputy Director of the Hong Kong and Macao Affairs Division of the Hong Kong and Macao Affairs Office of Jiangsu Provincial People's Government; Lv Jing, Director of the Hong Kong and Macao Affairs Office of Nanjing Municipal People's Government; and Chen Zhihai, Deputy Mayor of the Jiangning District People's Government, attended the symposium.

 

 

 

Paul Chan Mo-po stated at the symposium that this visit gave him a deep sense of Chia Tai Tianqing's vibrant development, and he was particularly impressed by the company's large gathering of high-quality young scientific and technological talent. Paul Chan Mo-po pointed out that in the next five years, Hong Kong will continue to consolidate and enhance its status as "four centers and one highland". Hong Kong not only has the financing advantages of an international financial center but also possesses a professional service system aligned with international standards, as well as advantages in international data resources and talent aggregation. It can provide strong support for outstanding innovative enterprises from the mainland in areas such as aligning with international standards, attracting scientific research talent, and expanding into overseas markets. He said that Nanjing has profound scientific and educational resources, industrial foundations, and innovation capabilities. Hong Kong will further deepen technological innovation and industrial collaboration between the two places, promote complementary advantages and common development, and help more Chinese enterprises grow into globally competitive multinational corporations.

 

 

Cheng Cheung Ling stated that from the early days of a relatively weak pharmaceutical industrial base, to gradually establishing an independent R&D system and perfecting advanced manufacturing capabilities, and now to forming a diversified innovative technology platform, the development of Chia Tai Tianqing has always been in sync with the progress of China's pharmaceutical industry. In the early days of its establishment, facing inadequate infrastructure and scientific research conditions, the company insisted on investing its operational accumulations into technological breakthroughs and talent development. It gradually built a technological "moat" with industry competitiveness, and a large number of young scientific researchers also grew through project practice, injecting vitality into the company's continuous innovation. Facing reforms in the medical and health system, changes in the industry's competitive landscape, and the accelerated evolution of new technologies, the company has proactively adapted to the developmental requirements of the era, actively embraced policy and technological changes, continuously improved the construction of its technological innovation platform, and promoted more high-quality innovative achievements to benefit patients. Leveraging Hong Kong's international advantages, we will continue to increase R&D investment and industrial cooperation, and better serve the overall development of the country and Hong Kong through innovative development.

 

 

At the symposium, Chen Zhihai introduced the geographical advantages, industrial foundation, innovation ecosystem, and business environment of Jiangning District. He stated that as an open window of Jiangsu and an economically strong district of Nanjing, Jiangning possesses a complete industrial system, rich scientific and educational resources, and a high-quality business environment. It has gathered high-level universities such as China Pharmaceutical University and Southeast University, a number of high-level technological innovation platforms, and 370,000 market entities in fields like smart grids, artificial intelligence, and biopharmaceuticals. He pointed out that with Nanjing located on the banks of the Yangtze River and Hong Kong on the shores of the Fragrant Harbour, he looks forward to deepening connections and achieving win-win cooperation with all sectors in Hong Kong. He hopes to jointly promote exchange and cooperation in the service industry, co-develop technology innovation incubation, build a modern transportation hub, and work together to promote complementary advantages and mutual benefits between the two places, better serving the overall picture of two-way opening up and development.

 

 

Zhao Wei, Senior Vice President of Chia Tai Tianqing, introduced the company's innovative development achievements in recent years. Relying on the group-wide innovation system of SBP Group, Chia Tai Tianqing continues to build its innovative pipeline around its advantageous fields such as oncology, liver diseases, and respiratory diseases, and actively promotes AI-empowered drug R&D and global cooperation. In recent years, through cooperation with multinational pharmaceutical companies such as Sanofi, AstraZeneca, GSK, and Boehringer Ingelheim, the global influence of China's innovative drugs has been continuously enhanced. Since its listing in Hong Kong in 2000, SBP Group has always maintained close ties with Hong Kong. In recent years, the company has leveraged policy opportunities such as the "1+" new drug approval mechanism and the Named Patient Program (NPP) to accelerate the launch of innovative drugs in Hong Kong, and looks forward to working together in the future to bring more high-quality new drugs to the world via Hong Kong.

 

 

 

During the inspection, Paul Chan Mo-po and his delegation visited Chia Tai Tianqing's biological products manufacturing workshop and the Digital Intelligence Future Experience Center to gain an in-depth understanding of the company's development history, industrial layout, innovative R&D, and production and manufacturing. This inspection further enhanced the Hong Kong delegation's understanding of SBP Group and Chia Tai Tianqing, and also provided a new opportunity to deepen the exchange and cooperation in the biopharmaceutical industry between Jiangsu and Hong Kong.

 

Accompanying them were Alpha Lau, Director-General of Invest Hong Kong (InvestHK) of the HKSAR Government; Huang Kaiyi, Director of the Hong Kong Economic and Trade Office in Shanghai; and Bryan Peng, Executive Director of the Office for Attracting Strategic Enterprises (OASES). Chen Hui, Senior Vice President of Chia Tai Tianqing, and Lu Jiansheng, Assistant Vice President and General Manager of Shunxin Pharmaceutical, accompanied the visit.

 

Declaration:

The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.

Share: